NCT01815242View on ClinicalTrials.gov

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

336

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

January 15, 2025

Conditions
Breast Cancer
Interventions
DRUG

nab-Paclitaxel

DRUG

Gemcitabine

DRUG

Carboplatin

Trial Locations (1)

41061

Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, Mönchengladbach, Germany, Mönchengladbach

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

West German Study Group

OTHER

NCT01815242 - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter